Recent Work Inflazome Limited
Share This

Inflazome Limited

Monday, 12 September 2016

ByrneWallace acted for Inflazome Limited in connection with its recent Series A financing round for up to €15 million, which was led by venture capital firms Novartis Venture Funds and Fountain Healthcare Partners.

Inflazome is developing inhibitors of the inflammasome, a compelling biological target that regulates our innate immune response, now associated with a wide variety of diseases. In addition to assisting on the financing round, ByrneWallace advised on a licence agreement between UniQuest Pty Limited (the commercialisation arm of the University of Queensland), Trinity College Dublin and Inflazome. 

For further information on this transaction, please visit

The ByrneWallace team who advised on this transaction included Colin Sainsbury (Partner and Head of Life Sciences Group).